article thumbnail

STAT+: Eli Lilly opens a new legal front in its battle against compounded GLP-1s

STAT

To date, Lilly and its rival, Novo Nordisk, have filed dozens of suits against numerous companies involved in compounding versions of semaglutide and tirzepatide, the obesity and diabetes drugs known as GLP-1s. Those lawsuits alleged trademark infringement, false claims and unfair competition, but have so far yielded varying outcomes.

article thumbnail

STAT+: Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA

STAT

Over the past two years, patients seeking treatment have been turning to compounding pharmacies, which make cheaper copies of branded treatments and are legally allowed to do so only when the branded treatments are listed on the FDA’s shortage list.    Continue to STAT+ to read the full story…

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Compounders lose legal battle with FDA over removal of Eli Lilly’s weight loss drug from a shortage list

STAT

The move means that patients will no longer have access to cheaper versions from compounding pharmacies. Due to ongoing shortages of the Lilly drugs, compounding pharmacies were permitted to make copies that sold for substantially less.

article thumbnail

STAT+: Eli Lilly strikes Zepbound deal with Ro, amid questions about future of compounded GLP-1s

STAT

The deal marks a noteworthy development for Ro, which has been one of the major telehealth platforms providing compounded copies of GLP-1 obesity drugs during shortages of the branded treatments. Continue to STAT+ to read the full story…

article thumbnail

STAT+: FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period

STAT

That should have prohibited compounding pharmacies from continuing to make copies of the drug, as they’re allowed to do so only when a treatment is on the shortage list.

article thumbnail

STAT+: Novo Nordisk to sell obesity drug Wegovy direct to patients at lower price

STAT

Novo Nordisk will start selling its obesity drug Wegovy directly to patients at a reduced price, following a similar move from Eli Lilly as the two drugmakers compete for market share and try to draw patients away from compounding pharmacies that have been making cheaper copies of weight loss drugs.

article thumbnail

STAT+: Court ruling opens door to FDA action against Ozempic compounders

STAT

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy. Compounding pharmacies are legally allowed to make versions of branded treatments if the drugs are deemed to be in shortage by the FDA.